Added: Calvina Aucoin - Date: 28.02.2022 00:35 - Views: 38069 - Clicks: 2474
Study record managers: refer to the Data Element Definitions if submitting registration or information. The study will be double-blind placebo-controlled trial with participants randomly allocated to placebo and vaccine arms.Strangers Undress Each Other On A First Date - Undressed
The immunization schedule is two doses intramuscular injections deltoid with a days interval. For safety and immunogenicity, participants are categorized in two age groups, Adults years and Elderly 60 years and above. Safety database aims to detect adverse reactions with frequency of or higher in adults and in elderly. All participants will be followed up to 12 months. Interim preliminary efficacy analysis can be triggered by reaching the target of 61 cases. Primary efficacy analysis requires cases. Talk with your doctor and family members or friends about deciding to a study.
To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or information. Search for terms. Save this study.
Warning You have reached the maximum of saved studies Listing a study does not mean it has been evaluated by the U. Federal Government. Read our disclaimer for details. Last Update Posted : February 11, Study Description. Detailed Description:. Arms and Interventions. Participants aging years receiving two doses with days interval of placebo.
Participants aging 60 years or above receiving two doses with days interval of placebo.
Outcome Measures. Frequency of adverse reaction in the seven days following each immunization per age group. of virologically-confirmed symptomatic COVID two weeks after first dose of vaccine, regardless the vaccination schedule was completed. of virologically-confirmed and or serologically-confirmed SARS-CoV-2 infections two weeks after first dose of vaccine. Frequency of adverse reaction in the 28 days following each immunization per age group.
Frequency of virologically-confirmed severe COVID cases after receiving, at least, one dose of the vaccine. Frequency of adverse events of special interest after receiving, at least, one dose of the vaccine. of seroconversion responses to SARS-CoV-2 in the second week after each vaccination per age group in a subset of participants. of cell-mediated immune response against SARS-CoV-2 in the week two and four after the second vaccination per age group in a subset of participants. of seropositive responses to SARS-CoV-2 in the second week after each vaccination per age group in a subset of participants.
Eligibility Criteria. Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Inclusion Criteria: Adults 18 years of age or older; Healthcare professionals who work in direct contact care of people with possible or confirmed COVID cases; Agree with periodic contacts by phone or electronic means, and home visits; Show voluntary intention to participate in the study, documented by the informed consent form ed by participant. Exclusion Criteria: For females: Pregnancy confirmed by positive beta-hCG testbreastfeeding or intent to engage in sexual relations with reproductive intent without use of birth control methods in the three months following vaccination; Evidence of uncontrolled neurological, cardiac, pulmonary, hepatic or renal disease, according to anamnesis or physical examination.
ificant changes in treatment or hospitalizations due to worsening of the condition in the last three months are indicators of uncontrolled disease; Diseases with impaired immune system including: neoplasms except basal cell carcinomacongenital or acquired immunodeficiencies and autoimmune diseases not controlled according to anamnesis or physical examination.Chloe Ferry \u0026 Scotty T's Buckin' Story - Geordie Shore 10
Immunosuppressant therapy regimens include: antineoplastic chemotherapy, radiation therapy and immunosuppressants to induce transplant tolerance, among others. Use of immunosuppressive doses of corticosteroids within the three months prior to the enrollment in the study and planned use of immunosuppressive doses of corticoids within the three months following enrollment in the study. Continued use of topical or nasal corticosteroids is not considered an immunosuppressant; Received blood products transfusions or immunoglobulins within the three months prior to enrollment in the study, or planned administration of blood products or immunoglobulins within the two years following enrollment in the study; Suspected or confirmed fever within the 72 hours prior to vaccination or axillary temperature greater than Contacts and Locations.
Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials. More Information. National Library of Medicine U. National Institutes of Health U. Department of Health and Human Services. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Phase 3. Study Type :. Interventional Clinical Trial. Actual Enrollment :. Actual Study Start Date :. Actual Primary Completion Date :.
Estimated Study Completion Date :. Placebo Comparator: Adult - Placebo Participants aging years receiving two doses with days interval of placebo. Placebo Comparator: Elderly - Placebo Participants aging 60 years or above receiving two doses with days interval of placebo.
July 2, Key Record Dates.Brasil sex date
email: [email protected] - phone:(362) 297-6467 x 3673
11 Things to Know About Dating in Brazil